Boehringer's Giotrif gains best IQWiG outcome... and worst
This article was originally published in Scrip
Boehringer Ingelheim is the proud recipient of the best possible IQWiG benefit assessment outcome for lung cancer product Giotrif (afatinib). Unfortunately, the drug also received the worst possible outcome in a small subsection of patients. With the mixed bag of results, Boehringer is not celebrating yet, but this could be an important step to proving it can demonstrate clinical efficacy in one of Europe's toughest markets, which is essential for the company as it tries to compete with Roche's Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib).